StreetInsider.com News Articles

Form 144 Damora Therapeutics, Filed by: Firmani Lori

Mon, 22 Jun 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260622/26672369.html

Form 144 Damora Therapeutics, Filed by: Firmani Lori

Mon, 22 Jun 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260622/26672369.html

Form 8-K Damora Therapeutics, For: Apr 28

Wed, 17 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260617/26659698.html

Form 8-K Damora Therapeutics, For: Apr 28

Wed, 17 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260617/26659698.html

H.C. Wainwright Starts Damora Therapeutics (DMRA) at Buy

Thu, 11 Jun 2026 06:35:10 -0400

(Updated - June 11, 2026 6:35 AM EDT)

H.C. Wainwright analyst Mitchell Kapoor initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Buy rating and a price target of $45.00.

The analyst comments "DMRA offers value opportunity to own the biotech theme that keeps hitting—validated MOAs with next-gen iterations. After the theme has seen multiple successful runs across I&I, Damora brings the concept to hematology. We have seen the capital markets reward similar stories: Oruka (ORKA; Buy) is now a $3.5B+ market cap after appreciation on its half-life extended Skyrizi/IL-23 concept in psoriasis; Generate Bio (GENB; Buy) is >$1.5B market cap with

H.C. Wainwright Starts Damora Therapeutics (DMRA) at Buy

Thu, 11 Jun 2026 06:35:10 -0400

(Updated - June 11, 2026 6:35 AM EDT)

H.C. Wainwright analyst Mitchell Kapoor initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Buy rating and a price target of $45.00.

TD Cowen Starts Damora Therapeutics (DMRA) at Buy

Mon, 08 Jun 2026 05:32:16 -0400

TD Cowen analyst Marc Frahm initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Buy rating.

The analyst comments "DMRA is developing best-in-class molecules for validated targets in MPN disease. Lead asset DMR-001 is a mCALR targeted mAb for the treatment of ET and MF demonstrating 3-10x potency in vitro relative to the most advanced competitor molecule, with convenient SC dosing. 001's preclinical profile addresses the high unmet need for a disease-modifying therapy in mCALR-driven MPNs. Initiating at Buy."

For an analyst ratings summary and ratings history on Damora Therapeutics click here. For more ratings news on Damora Therapeutics click

TD Cowen Starts Damora Therapeutics (DMRA) at Buy

Mon, 08 Jun 2026 05:32:16 -0400

TD Cowen analyst Marc Frahm initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Buy rating.

For an analyst ratings summary and ratings history on Damora Therapeutics click here. For more ratings news on Damora Therapeutics click

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Wedbush Starts Damora Therapeutics (DMRA) at Outperform

Thu, 28 May 2026 06:53:54 -0400

Wedbush analyst David Nierengarten initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Outperform rating and a price target of $35.00.

For an analyst ratings summary and ratings history on Damora Therapeutics click here. For more ratings news on Damora Therapeutics click here.

Shares of Damora Therapeutics closed at $25.21 yesterday.

Form SCHEDULE 13G/A Damora Therapeutics, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260515/26506235.html

Form SCHEDULE 13G/A Damora Therapeutics, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260515/26506235.html

Form SCHEDULE 13G/A Damora Therapeutics, Filed by: Jain Global LLC

Fri, 15 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260515/26506005.html

Form SCHEDULE 13G/A Damora Therapeutics, Filed by: Jain Global LLC

Fri, 15 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260515/26506005.html

Form SCHEDULE 13G Damora Therapeutics, Filed by: Avoro Capital Advisors LLC

Fri, 15 May 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260515/26499946.html

Form SCHEDULE 13G Damora Therapeutics, Filed by: Avoro Capital Advisors LLC

Fri, 15 May 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260515/26499946.html

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Tue, 12 May 2026 16:05:00 -0400

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress –

– On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively –

– Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms –

– Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected